Navigation Links
Trillium secures additional financing on the strength of lead program and proprietary position around the CD200 immunoregulatory pathway

TORONTO, Sept. 18 /PRNewswire/ - Trillium Therapeutics Inc., a privately-held biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders, announced today that it has secured $12 million in new financing from its existing investors, VenGrowth Private Equity Partners, BDC Capital and Canadian Medical Discoveries Fund (CMDF).

"We are fortunate to have the continued support of some of Canada's premier venture capital investors, especially under these trying market conditions," commented Trillium CEO Dr. Niclas Stiernholm. "These funds will allow us to advance several programs into clinical development, elevating the company to a new level and opening up new strategic possibilities in 2009."

Trillium will use the majority of the proceeds to fund clinical trials of its lead product candidate, TTI-1612, a recombinant growth factor under parallel development for the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. TTI-1612 is on track to begin clinical testing by the end of 2008, and two additional trials are projected to commence in 2009. The company's two preclinical programs, a CD200-specific monoclonal antibody for the treatment of cancer, and a CD200Fc fusion protein for the treatment of autoimmune and inflammatory diseases, continue to hold promise and to generate strong scientific and commercial interest.

"Our continued support for Trillium is driven by the quality of the lead program TTI-1612, the strong patent position around the exciting new immunoregulatory target CD200, and management's proven ability to execute partnerships," added Dr. Luc Marengere, of VenGrowth Private Equity Partners, Trillium's largest investor.

About Trillium: Trillium Therapeutics Inc. is a private biopharmaceutical company specializing in innovative therapies of immune-mediated conditions, such as autoimmune and inflammatory disorders, as well as cancer. The company's lead program, a recombinant growth factor, is being developed for the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. Trillium has two preclinical programs targeting the CD200 immunoregulatory axis; a CD200-specific monoclonal antibody for the treatment of cancer and a CD200Fc fusion protein for the treatment of autoimmune and inflammatory diseases. The company has a broad network of external academic and industry R&D collaborations, including several license agreements with major US biotechnology companies.

SOURCE Trillium Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Althea Technologies Secures $12 M Credit Line to Continue Facility Growth and Expansion
2. Progenitor Cell Therapy Secures Industry Accreditation
3. BIOCOM Institute Secures Non-Profit Designation and Funding
4. Cara Therapeutics Secures $12.3 Million in Series C Extension Financing
5. OMTEC 2008 Boasts Record Attendance and Secures Premier Position as Must-attend for Orthopaedic Companies
6. Genta Secures Up to $40 Million Convertible Financing Facility to Fund Key Programs
7. Novasys Medical Secures $49.5 Million in Series D Financing to Expand Commercialization of Its Renessa(R) Treatment for Incontinence in Women
8. Veran Medical Technologies Secures $4.75M in First Institutional Funding
9. Northwest Secures US$4.0 Million in Debt Financing
10. D-Pharm Secures Funding From Israels Chief Scientists Office
11. Aerovance Secures $20 Million in Debt Financing
Post Your Comments:
(Date:10/12/2015)... SAN FRANCISCO , October 12, 2015 ... reach USD 6.49 billion by 2022, according to a new ... can be attributed to rise in incidence of oncology diseases ... detection market is expected to reach USD 6.49 billion ... Research, Inc. This growth in demand can be attributed to ...
(Date:10/12/2015)... 12, 2015  Patara Pharma, a clinical-stage biotechnology ... diseases and conditions, today announced the closing of ... Concurrent with the close of its sale of ... and Security Agreement with Silicon Valley Bank whereby ... Patara will use the funds from the financing ...
(Date:10/12/2015)... Belgium , Oct. 12, 2015 VolitionRx ... from a completed clinical study of its NuQ ® ... in the online issue of Clinical Epigenetics , the ... was conducted in collaboration with Lund ... Roland Andersson , MD, PhD, Professor of Surgery and Vice-Dean, ...
(Date:10/12/2015)... (PRWEB) , ... October 12, 2015 , ... LifeTrak ... the launch of LifeTrak Zoom, the world’s first amphibious fitness tracker that seeks to ... offers flexwear technology and accurate heart rate monitoring both in water and ...
Breaking Biology Technology:
(Date:9/29/2015)... , Sept. 29, 2015 ... employee productivity while also saving energy , Minimized ... as Low Power Active Mode and embedded Fujitsu PalmSecure ... Fujitsu today shows that good things ... and refreshed models to its enterprise desktop and mobile ...
(Date:9/28/2015)... YORK , Sept. 28, 2015 /PRNewswire/ ... announced today that its expedited traveler service ... innovative platform transforms travel, bringing a frictionless ... its members. "CLEAR offers our ... enhances customer service," said Jim Smith ...
(Date:9/28/2015)... SAN FRANCISCO , September 28, 2015 ... size is expected to reach USD 12.03 billion by ... to 2020. Technological advancements such as Backside Illumination (BSI) ... revenue growth over the forecast period.      ... the back of the chip to reduce loss and, ...
Breaking Biology News(10 mins):